Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505905 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1HTTATML3MBTL1 | |
| SCHEMBL18380643 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL29616919 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL10522006 | 0.85 | KDM4E (0.53) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL4159068 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL8855987 | 0.80 | KDM4E (0.58) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL31048531 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL7112634 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL31542580 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HTTATMLMNA | |
| SCHEMBL2089146 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HTTATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012149639-A1 | NOVEL LATE TRANSITION METAL CATALYSTS FOR SELECTIVE POLYMER FORMATION | RYERSON UNIVERSITY (CA) | 2012-11-08 | — | — | WO | claimed |
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20220372033-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-11-24 | — | — | US | disclosed |
| US-20220372033-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-11-24 | — | — | US | disclosed |
| EP-4038069-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021063915-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021063915-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2021-04-08 | — | — | WO | disclosed |
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | disclosed |
| WO-2017103615-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2012149639-A1 | NOVEL LATE TRANSITION METAL CATALYSTS FOR SELECTIVE POLYMER FORMATION | RYERSON UNIVERSITY (CA) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012069856-A1 | ANTIMALARIAL COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2012-05-31 | — | — | WO | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | NDUFB7, NDUFB3, NDUFB5 | KDM4E 4154/4885ALDH1A1 846/4885HTT 3353/4885 |
| US-20220372033-A1 | ANTIBACTERIAL COMPOUNDS | NDUFS3, SQOR, MT-ND4 | KDM4E 3545/4885ALDH1A1 1319/4885HTT 3316/4885 |
| US-20190151305-A1 | COMBINATION PRODUCT | NDUFB5, NDUFB7, NDUFB10 | KDM4E 4216/4885ALDH1A1 857/4885HTT 2944/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KDM4E 2191/4885ALDH1A1 3750/4885HTT 2761/4885 |
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | NQO2, NDUFS3, QARS1 | KDM4E 1533/4885ALDH1A1 1097/4885HTT 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.